JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Roche Anderson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Video Blog Blog Blog 11 May, 2021 Author Etain Lavelle Huntington's disease research suffered a double whammy after Swiss pharmaceutical giant Roche Holding AG halted late-stage trials of an experimental medicine and Wave Life Sciences Ltd. abandoned two drug studies for futility. Roche stopped dosing patients with tominersen after an independent data monitoring committee questioned whether the drug's benefits outweighed its risks. "Obviously, it's a very sad situation when we have to stop a pivotal program in a disease like Huntington's where the...